Aberrations of 13q occur frequently in prostate cancer and this chromosome contains two known tumor suppressor genes, BRCA2 and Rb1. This study analysed 13q LOH, DNA ploidy, BRCA2 mutation and pRb expression in prostate cancers. In total, 13q deletions were found in 18 of 36 tumors but did not correlate with histological grade, stage or DNA ploidy. Two smallest regions of overlapping deletions were de®ned: one¯anked by D13S218 and D13S153; the other¯anked by D13S31 and D13S137. BRCA2 was less frequently deleted whereas Rb1 did have a high frequency of deletion. None of the two genes was located in any of these two regions. Furthermore, BRCA2 mutation was not found in the ®ve tumors where deletions had involved the BRCA2 locus. Neither did the Rb1 deletion correlate with absent pRb expression. In addition, tetraploidy was found in 14 out of 25 tumors analysed and correlated with aberrant pRb expression. Our results indicate that 13q deletion is an early non-random event. Tumor suppressor genes other than BRCA2 or Rb1 may be the target of 13q deletions. Aberrant pRb expression may not re¯ect the two-hit Rb1 inactivation but may be involved in the tetraploidization of prostate cancer cells.
Introduction
Aberrations of the long arm of chromosome 13 occur frequently in many types of tumors (Cletonjansen et al., 1995; Cooney et al., 1996; Li et al., 1994; Maestro et al., 1996; Pearce et al., 1996; Radford et al., 1995; Yang et al., 1992; Zhang et al., 1994) . So far two tumor suppressor genes (TSG) have been identi®ed on this chromosome: the retinoblastoma gene (Rb1) on 13q14.2 and the breast cancer susceptibility locus 2 (BRCA2) on 13q12.1 (Lee et al., 1987; MacGee et al., 1989; Wooster et al., 1995) . Rb1 is a cell cycle regulator which is involved in both hereditary and sporadic retinoblastoma, while BRCA2 mutations have been described in a subset of families with site speci®c breast cancer only (Oddoux et al., 1996; Phelan et al., 1996; Thorlacius et al., 1996; Wooster et al., 1995; .
In prostate cancer, somatic deletions of chromosome 13q have been frequently observed both by comparative genomic hybridization (CGH) and loss of heterozygosity (LOH) analysis (Cher et al., 1996; Cooney et al., 1996; Visakorpi et al., 1995) . The Rb1 locus is frequently deleted, and in one prostate cancer cell line a 103 bp deletion of the promoter region was observed with concomitant loss of the wild type allele, suggesting inactivation of this TSG by a two-hit mechanism (Bookstein et al., 1990; Riley et al., 1994) . Furthermore, immunostaining studies have revealed that the Rb1 expression is frequently decreased or absent in a signi®cant proportion of sporadic prostate cancers (Phillips et al., 1994) . However, screening for somatic mutations in Rb1 have given negative results also in the studies where larger series of tumors have been examined (Kubota et al., 1995; Sarkar et al., 1992; Tricoli et al., 1996) . On the other hand, in one study on families with hereditary breast cancer attributable to BRCA2, the male carriers have a 3.3-fold increased risk of developing prostate cancer as compared to non carriers (Wooster et al., 1995) . Thus, the importance of the BRCA2 gene in sporadic prostate cancer can also be anticipated.
Two approaches can be used to identify a candidate gene to be a TSG in sporadic cancers. One is to identify the somatic mutation coupled with loss of the normal chromosome homologue and the other is to observe the gene deletion in combination with absent or aberrant gene expression. These two approaches were used in the present study to investigate the involvement of BRCA2 and Rb1 in sporadic prostate cancer. The results indicate that deletion of chromosome 13q is an early non-random event, and that neither BRCA2 nor Rb1 was the targets but instead other putative TSGs might be located nearby.
Results

Overview of 13q losses in prostate cancer
The losses observed (Figure 1 ) either resulted in complete absence of one of the constitutional alleles in the tumor (pure LOH) or a signi®cantly decreased intensity, but not complete loss of one constitutional allele (allelic imbalance). The decrease of the intensity was not always related directly to the tumor cell content of the tissue sample from which the tumor DNA was derived. In both types of LOH, the retained allele had usually stronger signal intensity as compared to the corresponding allele in the normal DNA ( Figure  1 ).
In total, 18 out of 36 (50%) prostate cancers displayed LOH with at least one out of the eight markers analysed (Figure 2 ). The most frequently deleted locus was D13S153 (within Rb1) with nine out of 26 (35%) informative tumors showing LOH. From this central point of 13q loss, the frequency of LOH gradually decreased in both proximal and distal directions (Figure 2) . Tumor B1 had a break point proximal to D13S31ca and lost all the ®ve proximal loci. In contrast, tumor D4 had a break point distal to D13S218 and all the four distal markers showed deletion (Figure 1) . However, the LOH region of tumors B8 and D9 did not overlap with the LOH region of tumors C2, D3 and E6 (Figure 2) , thus, two smallest regions of overlapping deletions (SRO) were observed. For the proximal SRO (SRO1), LOH of tumors B8, D9 de®ned a distal limitation with marker D13S153 and LOH of tumors D4, D7 and E5 a proximal limitation with marker D13S218. Likewise for the distal SRO (SRO2), the LOH of tumor D3 de®ned a distal¯anking marker D13S137 and the LOH of tumors D1 and E5 a proximal¯anking marker D13S31ca ( Figure 2) .
As DNA ploidy may re¯ect the total cancer genome instability, the two LOH regions were analysed relating to DNA ploidy, however, neither of the regions was associated with a special pattern of DNA ploidy (Tables 1 and 2 ). No correlation was found between these two regions and histological grade, stage, or origin of tumor material (Table 2) .
No somatic BRCA2 mutation in sporadic prostate cancer
The LOH frequency of the BRCA2 gene was low (Figure 2 ): only two (B1, D1) out of 27 (7%) informative tumors showed LOH at D13S171 (within the BRCA2 gene) and only ®ve tumors (B1, B6, C7, D1, D9) showed a deletion which may involve the BRCA2 locus (D13S260-D13S171-D13S267). The BRCA2 locus was not included in any of the two SROs observed (Figure 2 ). Five tumors for which the LOH might have involved the BRCA2 locus and a further two tumors (B7, C9) which retained both copies of BRCA2 locus were analysed for mutation in the BRCA2 coding region. A base substitution, G10338 to A, was found in tumor B1 but this substitution did not alter the amino acid Argentine. No other mutations were detected in these seven tumors.
pRb expression patterns in prostate cancer
The expression of pRb in tumor cells demonstrated three patterns: pRb expression limited to the nucleus (nuclear pRb), pRb expression in both nucleus and cytoplasm (ectopic cytoplasmic pRb), and complete absence of pRb. In nuclear pRb positive cases, tumor cells showed a heterogeneous expression pattern with only a few cells being positively stained. In cytoplasmic pRb positive tumors, tumor cells always maintained nuclear pRb expression and were usually homogeneously stained (Figure 3 ). In all cases with absent pRb expression, almost no tumor cells had positive staining at all. However, disregarding the expression pattern of pRb in the tumor cells, the surrounding lymphocytes as well as the interstitial stromal cells always demonstrated only nuclear pRb staining.
In total, 34 of the 36 prostate tumors were analysed for pRb expression and 22 showed aberrant expression: 11 with ectopic cytoplasmic expression and 11 with absent expression (Table 3 ). The expression of ectopic cytoplasmic pRb was mainly observed in well dierentiated primary tumors, in contrast to the absent expression of nuclear pRb in poorly differentiated and metastatic prostate cancers (Table 3) .
No correlation of Rb1 LOH and pRb expression Table 1 shows the data of Rb1 LOH and pRb expression in each tumor. Of nine tumors with LOH at D13S153 (Rb1), four (44%) maintained and ®ve (56%) lost nuclear pRb expression (Table 3) .
Figure 1 LOH analysis of prostate cancer case D4. Retention of heterozygosity at markers D13S260, D13S171, D13S267 and D13S218; LOH at markers D13S153 (pure LOH), D13S319 (allelic imbalance), D13S31ca (allelic imbalance) and D13S137 (pure LOH). Arrows point out the lost allele in the tumor DNA. N: normal. T: tumor
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Primary: primary prostate cancer. LN: regional lymph node metastasis from prostate cancer. Brain: brain metastasis from prostate cancer. The letter in WHO grading system stands: W for well dierentiated, M for moderately dierentiated, P for poorly dierentiated and U for undierentiated. LOH: loss of heterozygosity. The Rb 1 LOH is presented by the LOH at D13S153 which is within the gene. RT: retain of both alleles. NI: non-informative. pRb Nucl: pRb nuclear expression. pRb Cyto: ectopic pRb cytoplasmic expression. +: positive. 7: negative. In DNA ploidy, the letter stands: D for diploidy, T for tetraploidy and A for aneuploidy. The cell in the table without data means no data in this item 
Discussion
LOH presents the imbalance ratio between the numbers of the homologous chromosomes. In spite of indicating the secondary event to speci®c TSG mutation, LOH may also re¯ect the general instability of the cancer cell's genome. This type of LOH occurs randomly and is related to parameters which roughly re¯ect the whole genomic alteration, such as DNA ploidy. We have found 50% of prostate tumors showing LOH at one or more 13q markers and no correlation between 13q LOH and DNA ploidy, indicating 13q deletion to be an early, non-random, and independent chromosomal alteration. The frequently deleted region on 13q in these 36 prostate cancers was in agreement with the lost region detected by previous CGH analyses (Cher et al., 1994; Visakorpi et al., 1995) . However, in the LOH mapping (Figure 2) , two independent smallest regions of overlapping deletions were further de®ned. The distal region was¯anked by marker D13S31ca and D13S137 (Figure 2 ) which overlaps the region described in a previous LOH analysis (Cooney et al., 1996) . The proximal region¯anked by markers D13S218 and D13S153 (Figure 2) has not been described before (Cooney et al., 1996) . These two regions may suggest the existence of more than one TSG.
The BRCA2 gene has been suggested to be a candidate but it was not located within these minimal regions (Figure 2) . Lack of mutation in the coding region in tumors with LOH at the BRCA2 locus further exclude the BRCA2 gene as being involved in sporadic prostate cancer.
The Rb1 gene spans approximately 200 kb DNA of 13q14 (Lee et al., 1987; McGee et al., 1989) . Marker D13S153 which is located within the gene had the highest frequency of LOH (Figure 2) . However, this marker seems not within the two SROs observed (Figure 1) . We also observed a lack of concordance between LOH with D13S153 (Rb1) and aberrant pRb expression (Tables 1 and 3) as reported in a previous study (Cooney et al., 1996) . In particular, tumors with Rb1 LOH presented also normal nuclear pRb expression (case B5, D6, D7 and E3), indicating the existence of an intact copy of the Rb1 gene (Table 1) and contradicting the two-hit inactivation mechanism (Tables 1 and 3 ). This may further disqualify the Rb1 gene to be the target of 13q deletions.
Other candidate genes in the proximal critical region include the serotonin receptor subtype 2 (HTR2) gene and the gene for an orphan G-protein coupled receptor (U16) which may need to be investigated. Both genes encode Gprotein coupled receptors which have wide biological activities (Hsieh et al., 1990; Herzog et al., 1996) . HTR2 is mapped centromeric to Rb1 on 13q14.2, while U16 is located in the intron 17 or Rb1 (Hsieh et al., 1990; Herzog et al., 1996; Schuler et al., 1996) . In the distal critical region, one TSG candidate may be the DBM gene which has been found to be homozygously deleted in B cell malignancy (Liu et al., 1995) . However, the exact physical distance of the marker D13S319 from the DBM gene is unknown (Figure 2) .
A previous study has shown that mouse embryonic ®broblast (MEF) cell line with null pRb function when exposed to mitotic spindle inhibitors has a strong tendency of polyploidization via whole genome duplication (Leonardo et al., 1997) . Our results further showed an association between pRb aberration and tetraploidy in a subset of tumor materials from prostate cancer patients (Table 3 ). The clinical importance of this observation needs further investigation.
In summary, this study has shown the importance of 13q deletion in prostate cancer. The alteration of BRCA2 gene is rare and does not play an important role in this tumor. Aberrant expression of pRb may not re¯ect a two-hit inactivation of the Rb1 gene but may cause the tetraploidization of a subset of prostate cancers. The result suggests the existence and importance of other yet unidenti®ed genes on chromosome 13q in prostate cancer.
Materials and methods
Prostate cancer patients
Diagnoses of prostate cancer in 36 patients were con®rmed by histopathological examination of the surgical specimen. The mean age at diagnosis was 63 years (ranges 52 ± 72). The disease extent (Table 1) was determined according to Whitemore and Jewitt staging system (Jewitt, 1975; Whitemore, 1956 ). None of the 36 patients was subjected to any hormonal or radiation therapies prior to surgery.
Prostate cancer tissue
Immediately after the specimen was removed, a horizontal section across the tumor nodular lesion was made. Tumor tissue was sampled inside the nodule to avoid contamination of surrounding normal tissue. One piece of the sample was paran embedded and used for pRb immunostaining, and DNA ploidy measurement. The other piece was snap frozen in 7708C and used for DNA extraction. The representativity of the tissue was estimated by histopathologic examination and only samples which contained 50% or more tumor cells were included in the study. Each item refers to Table 1 Tumor suppressor genes on 13q in prostate cancer C Li et al
Of 36 tumor samples, 25 were from primary tumors, seven were from lymph node metastases, and four were from brain metastates. The dierentiation of prostate cancer (Table 1) was estimated according to the World Health Organization's prostate cancer grading system (Mosto® et al., 1980) .
DNA isolation
High molecular weight DNA was isolated from matched pairs of peripheral leukocytes and tumor samples using standard methods.
LOH analysis
Eight markers on 13q were used: D13S260-D13S171 (within BRCA2)-D13S267-D13S218-D13S153 (within Rb1)-D13S319-D13S31ca-D13S137 (Figure 1 ). The order of the markers is according to the Human Genome Data Base (GDB). D13S319 is located within the homozygously deleted DBM (disrupted in B cell malignancy) region. D13S31ca was synthesized by the Nordic Human Genome Mapping Program at the Uppsala University Hospital. Other markers were supplied by Research Genetic Inc. (Huntsville, AL). The sequences and location of all the markers used can be found in the GDB.
The technical aspects of the PCR and microsatellite analysis were described previously (Liu et al., 1995) . LOH was de®ned as a complete absence of or signi®cantly decreased signal intensity of one of the constitutional alleles in the tumor DNA and can be unambiguously detected by the naked eye (Figure 2) . The result was reviewed by three investigators (C. Li, CL and USRB).
The BRCA2 gene mutation analysis
The details for the single strand conformational analysis (SSCA) and direct DNA sequencing of the BRCA2 gene have been published before (Phelan et al., 1996) . In short, 26 coding exons of the gene were ampli®ed using 55 dierent fragments of 200 ± 300 bp each, and the PCR products were run on MDE gels. When a SSCA shift was seen, the shifted band was excised from the gel, puri®ed and sequenced using a 377 Automated Fluorescent Sequencer (Applied BioSystems, CA).
pRb immunostaining
The immunostaining was performed according to a standard avidin-biotin complex (ABC) procedure on 3 mm thick slide of paran embedded tissue selection. The pRb monoclonal antibody, PMG3-245 (PharMingen), speci®cally recognizes the pRb epitope of amino acid residue 300 ± 380 (DeCaprio et al., 1988) . The dilution of the primer was 1 : 200. One normal brain tissue and 10 tissues of histologically con®rmed benign prostatic hyperplasia were used as controls in each experiment. The corresponding slide of hematoxylin and eosin staining was used to distinguish the tumor cells from surrounding stroma as well as in®ltrating lymphocytes.
If the cell nucleus alone or together with cytoplasm was positively stained it was regarded as a pRb positive cell. A tumor with pRb negative staining was de®ned as in a ®eld under a 10610 times magni®cation less than 1% of over all tumor cells was pRb positive. Three investigators (C Li, CL and USRB) independently evaluated all the immunostaining slides and the ®nal judgement was reviewed by the pathologist (GA).
DNA ploidy analysis
The detailed procedure was described before (Steinbeck et al., 1994) . Brie¯y, paralleled with pRb immunostaining, a 4 mm thick section was prepared for Feulgen staining. The DNA content of individual tumor cell was measured in a TV-based microscopic image analysis system. In each slide, at least 100 tumor cell nuclei were counted (Figure 3) . The DNA content pro®le was recorded and compared with an internal diploid standard obtained from the measurement of at least 20 normal cells.
Statistical analysis
The 36 tumors were divided into three subgroups according to the origin of the tumor material analysed: primary tumors, lymph node metastases and brain metastases (Tables 1 ± 4). To facilitate the statistical analysis, the WHO tumor grading system was integrated into two groups (Tables 2 ± 4): well to moderately dierentiated (W-M) and moderately poor to undierentiated (MP-U). For the same reason, the prostate cancer stage was integrated into two groups (Tables 1 ± 4): stage A-B and stage C-D. Fisher's and Pearson's tests were used to analyse these categories each in association with 13q LOH, DNA ploidy pattern and pRb expression pattern. The same tests were also used to analyse the association between pRb expression pattern, the Rb1 LOH, and DNA ploidy pattern.
